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Familial breast and ovarian cancers are often defective in homologous 
recombination (HR) due to mutations in the BRCA1 or BRCA2 genes. Cisplatin 
chemotherapy or poly(ADP-ribose) polymerase (PARP) inhibitors are tested   
for these tumours in clinical trials. In a screen for novel drugs that selectively 
kill BRCA2-defective cells, we identified 6-thioguanine (6TG), which induces 
DNA double-strand breaks (DSBs) that we show are repaired by HR. 
Furthermore, we show that 6TG is as efficient as a PARP inhibitor in selectively 
killing BRCA2-defective tumours in a xenograft model.  Spontaneous BRCA1 
defective mammary tumours gain resistance to PARP inhibitors through p-
gycoprotein expression. Here, we show that 6TG efficiently kills such BRCA1 
defective PARP inhibitor resistant (PIR) tumours. We also show that 6TG can 
kill cells and tumours that gained resistance to PARP inhibitors or cisplatin 
through genetic reversion of the BRCA2 gene. Although HR is reactivated in 
PIR BRCA2-defective cells, it is not fully restored for the repair of 6TG-induced 
lesions. This is likely to be due to several recombinogenic lesions being 
formed after 6TG. We show that BRCA2 is required for survival also to 
mismatch repair-independent lesions formed by 6TG, which do not include 
DSBs. This suggests that HR is involved in repair of 6TG-induced DSBs as well 
as mismatch repair-independent 6TG-induced DNA lesion. Altogether, our data 
show that 6TG efficiently kills BRCA2-defective tumours and suggest that 6TG 
may be effective in the treatment of advanced tumours that have developed 
resistance to PARP inhibitors or platinum-based chemotherapy.  
 
 
Breast cancer is the most common cancer in women in the Western world today and in the 
UK, breast cancer incidence rates have increased by more than 50% over the last 25 years.  
Familial mutations in the breast cancer susceptibility genes BRCA1 or BRCA2 are associated 
with an increased risk of several cancers, particularly breast, ovarian and prostate cancer (1). 
The proteins encoded by these genes both play important roles in homologous recombination 
(HR) repair (2-4) and it is likely that their tumour suppressor function is explained by their 
role in reducing mutation rates (5). This hypothesis is also supported by the observation that 
proteins with related functions have also been linked with a predisposition to developing 
breast cancer, i.e., CHEK2 (6), ATM (7), PALB2 (FANCN) (8-10) and BRIP1 (BACH1) (11).  
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HR-defective cells are characterised by hypersensitivity to crosslinking agents, which is 
thought to be related to a role of HR in bypassing inter-strand crosslinks during DNA 
replication (12). HR-defective cells are also hypersensitive to poly(ADP-ribose) polymerase 
(PARP) inhibitors (13, 14). This involves PARP1 having a role in DNA single-strand break 
(SSB) repair (15), which results in suppression of HR (16). PARP inhibitors may increase the 
amount of SSBs, which collapse into DNA double-strand breaks (DSB) at replication forks, 
requiring HR for repair (17). In the absence of HR, these DSBs are not repaired, resulting in 
HR defective cells such as BRCA1- and BRCA2-mutated cancers, which are therefore 
hypersensitive to PARP inhibitors (13). In the clinic, PARP inhibitors efficiently killed 
BRCA1- and BRCA2-defective tumours in a phase I-II clinical trial (18). However, acquired 
resistance to PARP inhibitor is a problem and may involve either additional mutations in the 
BRCA1 or BRCA2 genes that result in restoration of the C-terminal part of the proteins (19-
21) or up-regulation of Abcb1a/b genes encoding P-glycoprotein efflux pumps (22). Although 
the extent of resistance that can be acquired by these mechanisms is unclear in humans, it 
suggests that the discovery of agents that may overcome such resistance mechanisms merit 
further investigation.  
 
MATERIALS AND METHODS 
Chemicals 
All chemicals were obtained from Sigma unless stated otherwise, AG014699 was provided 
Pfizer GRD, La Jolla, and KU0058948 and olaparib by KuDOS Pharmaceuticals, 
(Cambridge, UK). AG014699 and KU0058948 compounds were dissolved at 10 mM in 100% 
dry DMSO and stored at -20
o
C, it was diluted in culture medium to give the final desired drug 
concentration in 1% DMSO with control cultures exposed to 1% DMSO alone. The NCI 
diversity and mechanistic set were obtained from NCI (Bethesda, MA) and stocks were 
maintained in 96-well plates in DMSO (stock concentration 1 mM (mechanistic set) and 10 
mM (diversity set).  
Cell culture and isolation of PARP inhibitor resistant cells. The HCT116 and 
HCT116+Chr3 were obtained from Dr Bert Vogelstein, U2OS cell line was obtained from 
ATCC, Capan-1 and resistant Capan-1 clones from Dr Toshiyasu Taniguchi, AA8, irs1SF and 
CXR3 cells from Dr Larry Thompson and V-C8 and V-C8B2 cells previously isolated (4).  
All cells were grown in Dulbecco’s modified Eagle’s Medium (DMEM) with 10% foetal 
bovine serum and penicillin/ streptomycin at 37°C under an atmosphere containing 5% CO2.  
shRNA depletion of BRCA2 
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Depletion of BRCA2 expression in U2OS or HCT116 cells was obtained from the stably 
integrated regulatable expression of BRCA2 shRNA using the BLOCK-iT™ Inducible H1 
RNAi Entry Vector Kit from Invitrogen, according to the manufacturers protocol (Invitrogen, 
Sweden). The target sequence introduced was AAC AAC AAU UAC GAA CCA AAC UU 
(23).  
Western Blot 
Proteins from cell lysates were separated and detected using Western blotting as previously 
described (24). The primary antibody was an anti-rabbit BRCA2 antibody (Santa Cruz, H299) 
diluted 1:500 in blocking solution. 
Screening procedure 
U2OS BRCA2 shRNA cells, were grown in the presence or absence of 2 mg/ml of dox for 2 
days, plated in 96 wells plates (2000 cells per well) in the presence or absence of doxycyclin, 
and the next day treated with test compounds (at a concentration 10 mM) from the NCI 
library. After 72 hours WST-1 cell proliferation reagent was used in order to determine the 
cells viability as described earlier (25).  Compounds from the library that selectively 
suppressed the growth of BRCA2 defective cells, but had only modest effects on BRCA2 
proficient cells were selected. 
Colony formation assay 
Cells were plated into 6 well plates at a density of 200 cells/well.  The next day the cells were 
treated with selected compounds at a range of concentrations, for different time periods (from 
3 h up to 6 days). After 1 week (for VC-8 and VC-8+B2 cells and PIR clones) or 2 weeks (for 
U2OS cells), when colonies could be observed, the colonies were fixed and stained with 
methylene blue in methanol (4 g/l). Colonies consisting of more than 30 cells were 
subsequently counted. In addition, exponentially growing VC-8, VC-8+B2 and PIR clones 1C 
and 2B were exposed to varying concentrations of AG014699 for 24 hr or 6TG for 48 hr prior 
to seeding in 90 mm dishes in drug-free medium for colony formation. Colonies were fixed 
and stained with crystal violet 10-14 days later and counted on an automatic colony counter 
(Oxford Optronix, Oxford UK) 
Pulsed-field gel electrophoresis 
Cells were treated with 6TG, collected by trypsinisation, resuspended in 1% InCert-agarose 
(in 37°C PBS) to a final concentration of 1.5 million cells/100ml and agarose plugs were 
separated by Pulsed-field gel electrophoresis as previously described (26).  
Immunofluorescence  
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Cells were grown on coverslips, treated, fixed, immunostained and analysed as previously 
described (24). The primary antibodies used were: mouse monoclonal anti-gammaH2AX at a 
dilution of 1:1000 and rabbit polyclonal anti-Rad51 (H-92, Santa Cruz) at a dilution of 
1:1000.  
PI staining and FACS analysis 
1x10
6
 cells were treated (or untreated) with compounds (such as B9 or 6-TG), collected by 
trypsinisation, and fixed in ice-cold 70% ethanol overnight at -20°C.  The cells were then 
rehydrated in PBS and stained with 50 mg/ml PI (propidium iodide) and 100 mg/ml RNAse A 
in PBS for 30 min RT. Samples
 
were further analyzed on a BD Biosciences FACScan. The 
data was analyzed by the WinMDI software version 2.8. 
In vivo experiments 
1 x 10
7
 exponentially growing VC8 or VC8-B2 cells were injected intramuscularly 
into the thigh of each CD1 nude (Charles River) mouse in 50 μl of PBS and handled and 
analysed as previously described (13). Tumour growth was assessed using the ratio of the 
diameter of the right (tumour bearing) to the left (normal) thighs. When thigh ratio reached 
between 1.3 and 1.5 mice were divided into groups for the following treatments: AG014699 
10 mg/kg (made up on day of use at 1 mg/ml in water) or 6TG 1.5 mg/kg (made up on day of 
use at 0.15 mg/ml in PBS) or saline (control) administered daily x 10 i.p.  
Generation of mammary tumors. Brca1
D5-13/D5-13
;p53
D2-10/D2-10
 mammary tumors were 
generated in K14cre;Brca1
F5-13/F5-13
;p53
F2-10/F2-10
 mice and genotyped as described (27). 
Orthotopic transplantations of tumor fragments into syngeneic animals and caliper 
measurements of mammary tumors were reported previously (22) 
 
RESULTS  
 
BRCA2 defective cells are hypersensitive to 6-thioguanine 
Individuals with inherited mutations in either BRCA1 or BRCA2 alleles have a high risk of 
developing breast cancer (1, 28). Here, we wanted to identify novel compounds to selectively 
kill BRCA2-defective cells. We developed a shRNA system to deplete the BRCA2 protein 
upon removal of doxycycline in U2OS sarcoma cells and we assayed the mechanistic and 
diversity set compound libraries from the NCI for compounds that selectively killed BRCA2-
depleted cells. Mercury-(2-amino-1, 9-dihydro-6H-purine-6-thionato-N7,S6)hexyl (B9) was 
identified in the screen as the most efficient compound to selectively kill BRCA2-depleted 
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U2OS cells (Supplementary Figure 1). We also found that this compound selectively killed 
BRCA2 defective V-C8 cells as compared to V-C8+B2 the isogenic cell line expressing 
BRCA2
WT
 protein (V-C8+B2) (4) (Supplementary Figure 1). The reason for selective killing 
of BRCA2-defective cells was likely to be explained by the role of BRCA2 in HR since cells 
defective in the RAD51 paralog XRCC3 were similarly sensitive to the B9 compound 
(Supplementary Figure 1).  
Structural analysis of the B9 compound revealed a strong resemblance to 6-thioguanine 
(6TG), which is a well established chemotherapy used to treat haematological malignancies in 
children and adults (29). We therefore decided to test the sensitivity of BRCA2-deficient cells 
to 6TG and found that survival was significantly lower than that of BRCA2-expressing cells 
(Figure 1A). Furthermore, we found that the BRCA2 protein is required to prevent apoptosis 
induced by 6TG, measured by subG1 population (Figure 1B) and the TUNEL assay (Figure 
1C).  
 
6-thioguanine selectively kills BRCA2 defective tumours  
To test the hypothesis that 6TG is useful for selective treatment of BRCA2-deficient 
tumours, we treated mice bearing xenografts derived from BRCA2-deficient V-C8 and wt 
BRCA2-complemented V-C8+B2 cells. Consistent with the hypothesis, we found that neither 
the PARP inhibitor, AG014699, nor 6TG had any effect on the outgrowth of the BRCA2-
proficient tumours (Figure 1D); in contrast, all mice with BRCA2-defective tumours 
responded to both 6TG and the PARP inhibitor equally, with significant growth delay and 3/5 
complete tumour regressions in both groups.  These results suggest that 6TG is as effective as 
the PARP inhibitor, AG014699, in selectively killing BRCA2-defective tumours. However, it 
should be noted that 6TG at 1.5 mg/kg caused greater loss of body weight than AG014699 
(Supplementary Table I) and was not tolerated at a higher dose of 3 mg/kg (data not shown).  
        
6-thioguanine induced DNA double-strand breaks are repaired by homologous 
recombination 
6TG is an anti-metabolite of purine metabolism and is incorporated into the DNA of 
mammalian cells in place of guanine during DNA replication (29). The incorporated 6TG 
(about 1 in 10
4
 bases) is then methylated in situ to 6-meTG by endogenous S-
adenosylmethionine and becomes a substrate for mismatch repair (MMR) in the second 
replication round to mediate its toxicity (30-33). As a measure of formation of DSBs in DNA, 
we looked at the nuclear levels of γH2AX in cells treated with 6TG and we found that γH2AX 
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foci formed with similar frequency in both BRCA2-deficient and -proficient cells (Figure 
2a,b).  This lack of discrepancy suggests that the hypersensitivity of BRCA2-deficient cells to 
6TG is due to an inability to repair DNA damage rather than a difference in the amount of 
damage introduced. We also found that γH2AX foci co-localised with RAD51 foci after 6TG 
treatment in BRCA2-proficient cells (Figure 2c), suggesting that the RAD51 protein is 
recruited to DSBs to repair the lesion by HR. In contrast, RAD51 foci did not form at 6TG-
induced γH2AX foci in BRCA2-defective V-C8 cells, suggesting that DSB repair is deficient 
in these cells. Using pulsed-field gel electrophoresis, we found that BRCA2 defective V-C8 
cells were unable to repair 6TG-induced DSBs compared to BRCA2-expressing cells 
(Supplementary Figure 2). To further investigate the role of HR in the 6TG induced DNA 
damage, we looked at the survival of cells defective in the RAD51 paralog, XRCC3 (irs1SF), 
and we found that these cells were considerably more sensitive to 6TG than AA8 control cells 
(Figure 2e). Altogether, these findings suggest that the sensitivity of BRCA2-defective cells 
to 6TG is due to their inability to perform HR repair. HR is important in repairing DNA 
damage caused by a wide range of mono- or bi-functional alkylating anti-cancer agents, for 
example the commonly used drugs, cisplatin and mitomycin C (34). To our knowledge, these 
results with 6TG represent the first time HR has been implicated in repair of thiopurine anti-
metabolite drugs. Interestingly, it has previously been shown that HR-defective cells are more 
sensitive to O6-methyl guanine lesions than cell lines with defects in other repair pathways 
(35, 36), a finding which corroborates the importance of HR in repairing lesions on the O6 
position of guanine.   
 
BRCA1-defective tumours that gained resistance to PARP inhibitors through P-
glycoprotein expression remain 6-thioguanine sensitive 
Increased expression from the Abcb1a and Abcb1b genes encoding the mouse drug efflux 
transporter P-glycoprotein (P-gp) explains resistance to the PARP inhibitor olaparib in 
BRCA1;p53-defective mammary tumours (22). Here, we wanted to determine if 6TG can 
target such PARP inhibitor resistant tumors. To test this, Brca1
D5-13/D5-13
;p53
D2-10/D2-10
 
mammary tumours derived from K14cre;Brca1
F5-13/F5-13
;p53
F2-10/F2-10
 mice were grown out 
and treated with olaparib as previously described (22). Small tumor fragments of an olaparib 
resistant tumor (T6-28) with 80-fold increased expression of the Abcb1b gene were 
transplanted orthotopically into syngeneic wild-type female mice. The animals were then 
treated with olaparib or 6TG when the tumor volume reached ~200 mm
3
. As expected, none 
of the Abcb1b overexpressing BRCA1;p53-defective tumours responded to olaparib treatment 
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(Figure 3). Interestingly, we found that tumours responded to 6TG (Figure 3). This shows that 
spontaneous BRCA1;p53-defective mammary tumours are sensitive to 6TG, and importantly, 
that PARP inhibitor resistant tumours in which resistance is caused by increased P-
glycoprotein-mediated drug efflux remain sensitive to 6TG. After the 10 day treatment with 
6TG tumours eventually grew back. However, such tumours were still responding to a second 
line treatment with 6TG, indicating that the tumours did not easily obtain resistance to 6TG.  
 
BRCA2-defective cells and tumours that gain resistance to PARP inhibitors 
through genetic reversion remain 6-thioguanine sensitive  
Mechanisms of acquired resistance to PARP inhibitors can also evolve through genetic 
reversion in BRCA2-defective cancer cells (20, 21). In such cases, a mutation in the BRCA2 
gene results in that the C-terminal part of the protein is retained and the protein overall 
functional in HR, despite missing a ssDNA binding domain (20, 21). In order to investigate 
this mechanism of resistance further, we made use of BRCA2-defective V-C8 clones selected 
for resistance to a PARP inhibitor (Gottipati et al 2010, submitted manuscript). All PARP 
inhibitor resistant (PIR) V-C8 clones harbour the same mutation, restoring the correct reading 
frame for BRCA2 and at the same time introducing a mutation within a highly conserved 
region in exon 15. This mutation affects a highly conserved arginine that was also identified 
in a family with breast and ovarian cancers (37) and was described in mitomycin C (MMC) 
resistant V-C8 cells (38). Thus, the reverted BRCA2 still has a defective ssDNA domain in 
the C-terminal part of the protein, as described earlier (20, 21), which restored HR as 
indicated by ability to form RAD51 foci in response to PARP inhibitor treatment 
(Supplementary Figure 3). We tested the sensitivity of PIR resistant clones 1C and 2B to the 
PARP inhibitor AG014699 and found that both clones had lost their sensitivity to PARP 
inhibitors (Figure 4a). 
We then tested the sensitivity of PIR V-C8 cells for cross-resistance to cisplatin and 
6TG. Parental V-C8 cells are highly sensitive to both cisplatin and 6TG, compared to the 
BRCA2-expressing V-C8+B2 cells (Figure 4b,c). As expected from previous studies (20, 21), 
PIR V-C8 clones exhibited resistance to cisplatin (Figure 4b). Surprisingly, we found that PIR 
V-C8 cells had not fully reverted to resistance to 6TG (Figure 4c), suggesting that 6TG may 
still kill PIR BRCA2 defective tumours that gained resistance through genetic reversion.  
We confirmed that BRCA2 revertant cells, that have acquired resistance to cisplatin, 
retain sensitivity to 6TG by using BRCA2 defective human pancreatic cancer cell line, 
Capan1, and 4 different independent cisplatin resistant Capan1 clones (20).  Clones 6 and 12 
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acquired resistance through an additional mutation in the BRCA2 gene that corrected the 
frameshift caused by the 6174delT mutation in Capan1 cells, while clones 10 and 11 do not 
have an additional BRCA2 mutation, lack BRCA2 protein expression and are likely to have 
reverted to cisplatin resistance through other unknown pathways (20 ). Interestingly, all 4 
cisplatin resistant clones showed equal sensitivity to 6TG as parental Capan1 cells 
(Supplementary Figure 4), providing additional evidence that PIR and cisplatin-resistant 
BRCA2-defective cancer cells are sensitive to treatment with 6TG.  
Next we wanted to test if 6TG also can retard outgrowth of PIR BRCA2 defective 
tumours that gained resistance through genetic reversion. To test this we treated mice bearing 
xenografts derived from PIR clone 2B, with a 10 day treatment with AG014699 or 6TG and 
found that PIR clone 2B tumours only responded to the 6TG treatment and not to the PARP 
inhibitor (Figure 4d; statistically significant in Mann Whitney test p<0.01). 
 
Differential sensitivity to anti-cancer drugs in genetically reverted BRCA2-
defective cells  
To gain further insights into the function of the restored BRCA2 protein carrying a 
mutation in the ssDNA binding domain, we further investigated the sensitivity of the PIR 
clones to a range of cytotoxic agents (Supplementary Figure 5). The PIR clones exhibited 
similar levels of resistance to temozolomide, camptothecin and ionising radiation as the V-
C8+B2 cells compared to the more sensitive V-C8 cells. Interestingly, the PIR clones were 
slightly more resistant to doxorubicin than the V-C8+B2, which were in turn more resistant 
then the V-C8 cells (Supplementary Figure 5d). Surprisingly, the V-C8 and the PIR clones 
were less sensitive to gemcitabine and paclitaxel than the V-C8+B2 cells (Supplementary 
Figure 5e,f). These data suggest that recombination defective BRCA1 and BRCA2 tumours 
will respond poorly to gemcitabine and paclitaxel treatments. The retained sensitivity to 6TG 
and resistance to gemcitabine and paclitaxel in the PIR clones is likely to be explained by the 
reverted BRCA2 gene which did not revert back to wild type, but retained a mutation in the 
ssDNA domain, which may impair HR induced by these agents. This ssDNA domain may be 
required for the BRCA2 response to 6TG and may prevent efficient repair of gemcitabine and 
paclitaxel induced lesions.  
 
6-thioguanine induces both a mismatch repair dependent and independent 
lesions that require HR repair.  
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Next, we wanted to understand the mechanism for PIR cells maintaining their sensitivity 
to 6TG. We analysed RAD51 foci and found that PIR V-C8 cells induced RAD51 foci as 
efficiently as V-C8+B2 cells in response to treatment with a PARP inhibitor, but not in 
reponse to treatment with 6TG, suggesting that the BRCA2 reverted protein is not fully 
proficient for 6TG-induced HR (Figure 5a). We also investigated the translocation of the 
RAD51 protein into the chromatin fraction, as this may be associated with the efficiency of 
RAD51 loading on to DNA and subsequent HR (39). We found that the RAD51 protein is 
more efficiently recruited to DNA after 6TG in V-C8+B2 cells than in the 1C clone and 
conversely that the RAD51 protein is more efficiently recruited to DNA in the 1C clone than 
V-C8+B2 following treatment with the PARP inhibitor, KU0058948 (Supplementary Figure 
6). Next, we investigated the repair of 6TG induced DNA lesions by γH2AX foci formation 
and find that, BRCA2 is required for efficient repair (Figure 5b). Interestingly, neither the 1C 
or 2B clones fully repaired the 6TG-induced DNA damage, suggesting their lack of efficient 
HR repair is the reason for their 6TG sensitivity.   
The reason for the differential response to 6TG and PARP inhibitors may be related to 
the production of different recombinogenic lesions in DNA. To test this hypothesis, we 
treated mismatch repair-defective HCT116 colorectal cancer cells and the same cells with 
restored mismatch repair function (HCT116+Ch3) (40) with 6TG, the PARP inhibitor 4-
amino-1,8-napthalimide (ANI) and cisplatin. We found that only the cytotoxicity of 6TG was 
dependent upon a functional mismatch repair pathway (Figure 6a; Supplementary Figure 7). 
Furthermore, the level of recombinogenic DSBs, measured by γH2AX foci, were dependent 
on mismatch repair after 6TG treatment, whereas generation of these lesions was unaffected 
by PARP inhibitor and cisplatin treatment in these cell lines (Figure 6b). Our data are in line 
with that toxic DSBs induced by 6TG are mismatch repair dependent (30), and it has 
previously been shown that HR induced by O6-guanine methylating agents depend on 
mismatch repair (41). This is also in line with our previous observation that 6TG-induced 
DSBs require HR for repair (Figure 5B; Supplementary Figure 2).  
There is a possibility that 6TG may produce another, mismatch repair independent HR 
substrate, given that the PIR V-C8 clones show an intermediate HR response to 6TG (Figure 
5). To test this we shRNA depleted BRCA2 in HCT116 cells to test if the absence of 6TG-
induced DSBs also abolish the requirements for HR for survival. Surprisingly, we find that 
mismatch repair defective HCT116 still requires BRCA2 for survival to 6TG, showing that 
6TG also produces a recombinogenic lesion that is independent of mismatch repair. 
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DISCUSSION 
Here, we report that cells and/or tumours defective in the HR genes BRCA1, BRCA2 or 
XRCC3 are hypersensitive to 6TG and that in the case of BRCA2 this can be reversed by 
introduction of a vector expressing the BRCA2 protein. We show that 6TG induced RAD51 
foci at 6TG-induced DSBs and that the DSBs are less efficiently repaired in BRCA2 defective 
cells, which correlates with increased toxicity in HR defective cells. This is to our knowledge 
the first time HR has been implicated in the repair of 6TG-induced DSBs.  
Interestingly, the opposite result is previously reported; that expression of BRCA1
WT
 in 
BRCA1 mutated HCC1937 breast cancer cells increase sensitivity to 6TG (42). However, this 
is unrelated to any role of BRCA1 in HR (42) and the BRCA1 mutation in HCC1937 cells is 
unlikely to affect HR, as RAD51 foci are efficiently induced by IR in these cells (43).  
Although PARP inhibitors have been shown to efficiently kill both BRCA1 and BRCA2 
defective tumours, resistance to therapy may develop within 18 to 77 weeks (18). Although, 
the exact mechanisms for PIR in patients remain unknown, it may involve expression of p-
glycoprotein efflux pumps as in mammary mice tumours (22) or through genetic reversion of 
either BRCA1 or BRCA2 (19-21). Here, we show that 6TG efficiently kills PIR BRCA1 
defective mammary tumours (Figure 3), which is likely explained by 6TG is not a substrate 
for p-glycoprotein (44). Furthermore, we show that 6TG can also kill genetically reverted 
BRCA2 defective cells and tumours. Altogether, these findings suggest that 6TG may be 
efficient in also killing advanced and drug resistant BRCA1 or BRCA2 defective tumours.  
Here, we find that PIR V-C8 clones do not completely revert back to a functional HR 
phenotype in response to 6TG (Figure 5), which likely explains their 6TG sensitivity. This 
suggest that there may be several lesions formed following 6TG treatment that trigger HR. 
For instance, we recently showed that HR is involved in restart at stalled replication forks, 
which does not involve DSB repair (45, 46). Thus, there is a possibility that 6TG may cause 
replication lesions other than mismatch repair dependent DSBs that trigger HR. In support for 
this notion, we find that mismatch repair defective HCT116 cells are sensitised to 6TG by 
depletion of BRCA2 in spite of already being defective in mismatch repair. This shows that 
both mismatch repair dependent and independent HR lesions are formed by 6TG. Also, this 
would explain the intermediate response in PIR V-C8 clones to 6TG.   
In conclusion, we show that 6TG can be efficiently used to selectively kill BRCA2 
defective tumours and that 6TG may be used as treatment for BRCA1 or BRCA2 mutant 
tumour which are resistant to cisplatin chemotherapy and/or PARP inhibitor therapy by 
various mechanisms.   
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Figure legends 
 
Figure 1 homologous recombination defective cells are hypersensitive to 
chemical 6TG. (a) 6TG selectively kill BRCA2 defective VC-8 cells in a colony 
formation assay. 6TG-induces apoptosis in HR defective VC-8 cells as measured by 
FACS analysis of the (b) subG1 population and (c) TUNEL staining. The average 
and standard deviation from at least three experiments is shown. (d) Tumour 
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outgrowth in xenograft mice (5 per group) following injection of V-C8 and BRCA2 
complimented V-C8+B2  upon i.p. treatment with 6TG and PARP inhibitor.  
 
Figure 2   homologous recombination is needed to repair the damage induced 
by 6TG.  Equal amount of DNA damage in V-C8 and V-C8+B2 cells following 6-
thioguanine treatment, as determined by (a) γH2AX foci (Cells containing more than 
10 foci were scored as positive) or (b) by Western blot. (c) RAD51 foci do not form in 
V-C8 cells upon 6TG induced DNA damage. RAD51 foci do form in V-C8+B2 cells 
and co-localise with γH2AX foci. (d) Quantification of RAD51 foci formed in V-C8 and 
V-C8+B2 cells after 6TG treatment. (e) 6TG selectively kills XRCC3 defective irs1SF 
cells in a colony formation assay as compared to wild type control (AA8). 
 
Figure 3 Response of the PARP inhibitor resistant Brca1D5-13/D5-13;p53D2-10/D2-10 
tumour T6-28 to 6TG. Animals carrying orthotopically transplanted tumours were 
treated with 1.5mg 6TG per kg i.p. daily on days 0-9 or 50mg olaparib per kg i.p. daily 
when the tumours reached a volume of 150-250mm3 (100% day0). When tumours 
relapsed back to 100% (arrows), a second treatment of 1.5mg 6TG per kg daily for 4 
consecutive days was tolerated. rs.  
 
Figure 4 6-thioguanine kills PARP-inhibitor and cisplatin- resistant BRCA2 
defective cells and tumours. Clonogenic survival in BRCA2 defective V-C8, BRCA2 
complimented V-C8+B2 and V-C8 PARP inhibitor resistant clones following treatment 
(a) PARP inhibitor AG014699; (b) cisplatin; (c) 6TG. The average and standard 
deviation from at least three experiments is shown. (d) Tumour outgrowth in 
xenograft mice following injection of PIR V-C8 clone 2B upon i.p. treatment with 6TG 
and PARP inhibitor. 6TG retards PIR V-C8 clone 2B tumour outgrowth (statistically 
significant in Mann Whitney test p<0.01).  The average and standard error from ten 
mice in each group is shown. 
 
Figure 5 PARP-inhibitor resistant BRCA2 defective cells partially activates HR 
in response to 6TG. (a) Quantification of 6TG and PARP inhibitor induced RAD51 
foci. BRCA2 complimented V-C8+B2 cells showed a significant increase in RAD51 
foci compared to PIR V-C8 cells upon 6TG treatment (24 hours after an 18 hour 
treatment with 1μM of 6-TG) (b) Quantification of repair of 6TG-induced  γH2AX foci. 
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HR defective V-C8 cells fail to repair 6TG-induced γH2AX foci, while V-C8+B2 cells 
repairs a majority of 6TG-induced γH2AX foci. PIR V-C8 clones show an intermediate 
repair of 6TG-induced γH2AX foci. The average and standard error of three 
independent experiments is depicted. Values marked with asterisks are statistically 
significant in T-test (* p<0.05; ** p<0.01; *** p<0.001). 
 
Figure 6 BRCA2 suppresses 6TG toxicity in mismatch repair deficient cells.  (a) 
Survival following continuous treatment with PARP inhibitor ANI, 6TG and cisplatin in 
HCT116 and HCT116+Ch3 cells. (b) γH2AX foci formation in hMLH1 defective 
HCT116 and hMLH1 complemented HCT116+Ch3 cells after a 24 hour treatment 
with 6TG and cisplatin or a 4 hour treatment with PARP inhibitor ANI. (c) Clonogenic 
survival in HCT116 and BRCA2 depleted HCT116 to increasing doses of 6TG. The 
average and standard deviation of three independent experiments is depicted. 
Values marked with asterisks are statistically significant in T-test (*** p<0.001). 
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FIGURE 3 
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FIGURE 5 
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Supplementary Online Figures S1-S7 
Issaeva et al 
 
Supplementary Table 1. Summary of efficacy and toxicity of AG014699 and 6TG 
against BRCA2 wt and mutant xenografts 
  Xenograft 
Time to Thigh ratio 2.5 
(days) 
Complete 
regressions  
Nadir body weight % 
starting weight (day 
occurred) 
Control V-C8 28,28,26,28,26 0/5 97 (4) 
6TG (1.5 
mg/kg) 
V-C8 32,>100,>100,>100,32 3/5 93 (6) 
AG014699 
(10 mg/kg) 
V-C8 >100,>100,>100,40,40 3/5 98 (10) 
Control V-C8+B2 27,33,27,29,29 0/5 96 (8) 
6TG 1.5 
mg/kg 
V-C8+B2 18,29,33,29,29 0/5 95 (10) 
AG014699 
(10 mg/kg) 
V-C8+B2 29,33,33,33,33 0/5 98 (10) 
   
Supplementary Table 2. Summary of efficacy and toxicity of AG014699 and 6TG 
against PIR V-C8 clone 2B. 
  
 Xenograft 
nadir body weight 
% starting weight  
(day occurred) 
time to Thigh ratio 2 
(days) 
Toxic death (day) 
Complete 
regressions  
Control 
VC8 Clone 
2B 
99( 7) 
6, 5, 6, 4, 4, 
6.5, 5, 6, 6, 6 
N/A 0/5 
6TG 1.5 
mg/kg 
VC8 Clone 
2B 
87(11) 
12, 6, 5.5, 8, 9, 
9, 9, 9, 9, 9 
N/A, 12*, N/A, 11*, 11*, 
11*, 11*, 11*, 11*, 12* 
0/5 
AG014699 
VC8 Clone 
2B 
100(0) 
5.5, 5, 5.5, 5.5, 4, 
4, 3, 3.5, 4, 4 
N/A 0/5 
* These animals died from a rapid infection. It should be noted that 6TG is used as an 
immunosuppressant and hence depletes the innate immune response present in CD1 nude 
mice. 
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Figure S1  B9 selectively inhibits the growth of BRCA2 deficient cancer cells. 
(a) Screening procedure  used to identify compounds that selectively inhibit growth of 
BRCA2 deficient cancer cells. Depletion of BRCA2 protein in U2OS cells stably 
transfected  with tet-regulable BRCA2 shRNA. (b) Viability of human osteosarcoma 
cells U2OS with tet-repressible BRCA2 shRNA treated with B9 from the original 
screen. B9 inhibits the survival of BRCA2 deficient cells in a colony formation assay 
in (c) U2OS with tet-repressible BRCA2 shRNA and (d) Chinese hamster VC-8 cells, 
which are defective in the BRCA2 gene, and VC-8+B2 cells supplemented with wild 
type BRCA2 expression. (e) chemical structures of b9 (Mercury-(2-amino-1, 9-
dihydro-6H-purine-6-thionato-N7,S6)hexyl-) and 6-thioguanine. (f)  B9 inhibits the 
growth of homologous recombination deficient cells. Colony formation assay upon 
treatment with B9 of parental AA8 cells and subline of this line deficient in Rad51 
paralog XRCC3, irs1SF. 
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Figure S2  Analysis of Repair of 6TG-induced DSBs by pulse field gel eletrophoresis 
in BRCA2 defective V-C8 and BRCA2 complemented V-C8+B2. 
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Figure S3 BRCA2 defective cells reverted to PARP inhibitor resistance by 
additional mutation in BRCA2 gene activate homologous recombination RAD51 
and γH2AX foci formation following a 24 hour PARP inhibitor treatment (KU0058948, 
1μM). 
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Figure S4  6-thioguanine kills PARP-inhibitor and cisplatin- resistant BRCA2 
defective cells. Clonogenic survival upon (a) 6TG, (b) cisplatin and (c) PARP 
inhibitor KU0058948 treatment in BRCA2 defective human pancreatic cancer Capan1 
cells and 4 independent cisplatin resistant clones. The average and standard 
deviation of three independent experiments is depicted.  
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Figure S5  Clonogenic survival of V-C8, V-C8+B2 and PIR V-C8 clones to (a) 
temozolomide, (b) camptothecin, (c) ionising radiation, (d) doxorubicin, (e) 
gemcitibine, (f) paclitaxel. 
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Figure S6  Western blot identifying RAD51, γH2AX and H3 isolated in the chromatin 
bound protein fraction in 1C clone and V-C8+B2 cells 24 hours after an 18 hour 
treatment with 1μM of 6-TG or 1μM of KU0058948. 
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Figure S7  6TG, PARP inhibitor (ANI), and cisplatin-induces apoptosis in mismatch 
repair proficient HCT116+Ch3 and mismatch repair defective HCT116 cells as 
measured by FACS analysis of the subG1 population.  
 
